Lindsey Spencer
Family · Cincinnati, OHNPI 1366748535
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,250 of the $52,851 with a category attached, or 62.9%. Fresenius USA Marketing, Inc. accounts for 94.0% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2024 at $21,765 and has fallen 70.6% since, to $6,390 in 2025. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $215.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$50K
- AstraZeneca$449
- Amgen$431
- Bayer$359
- Vifor Pharma, Inc.$278
- Calliditas Therapeutics US Inc.$245
- plus $1K from 20 others
What the payments were for
- Consulting fees$4,0008%
- Speaking & faculty fees$33,25063%
- Travel & lodging$10,20819%
- Food & beverage$5,39310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 111 | $49,695 |
| AstraZeneca(2 entities) | 14 | $449 |
| Amgen(2 entities) | 14 | $431 |
| Bayer | 18 | $359 |
| Vifor Pharma, Inc. | 11 | $278 |
| Calliditas Therapeutics US Inc. | 8 | $245 |
| Daiichi Sankyo Inc. | 11 | $206 |
| Ardelyx, Inc. | 8 | $180 |
| Otsuka America Pharmaceutical, Inc. | 9 | $166 |
| Nxstage Medical, Inc. | 5 | $159 |
| Akebia Therapeutics Inc | 4 | $89 |
| Travere Therapeutics, Inc. | 4 | $68 |
| OPKO Pharmaceuticals, LLC | 4 | $64 |
| Aurinia Pharma U.S., Inc. | 3 | $62 |
| Mallinckrodt Hospital Products Inc. | 3 | $58 |
| Boehringer Ingelheim | 2 | $41 |
| Hollister Incorporated | 1 | $40 |
| Pharmacosmos Therapeutics Inc. | 3 | $40 |
| Novartis | 2 | $40 |
| GSK | 2 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Veloxis Pharmaceuticals, Inc. | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Renalytix AI, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,851 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 109 | $276,903 |
| XphozahTenapanor Hcl | 21 | $80,351 |
| Sevelamer Carbonate | 101 | $23,335 |
| EliquisApixaban | 25 | $20,583 |
| Lanthanum Carbonate | 15 | $5,556 |
| Nifedipine ErNifedipine | 66 | $1,705 |
| Allopurinol | 62 | $505 |
| Hydralazine Hcl | 23 | $385 |
| Torsemide | 17 | $329 |
| Losartan Potassium | 36 | $245 |
| Furosemide | 38 | $155 |
| Pantoprazole Sodium | 12 | $152 |
| Amlodipine Besylate | 16 | $87 |
| Carvedilol | 26 | $84 |
| Ciprofloxacin Hcl | 17 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $49,695 | $276,903109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Cincinnati
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Bria BarjucaCincinnati$38K
- Jillian CowanCincinnati$20K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.